Krebs Biochemicals and Industries Limited
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various produ… Read more
Market Cap & Net Worth: Krebs Biochemicals and Industries Limited (KREBSBIO)
Krebs Biochemicals and Industries Limited (NSE:KREBSBIO) has a market capitalization of $12.03 Million (₹1.04 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #33887 globally and #1896 in its home market, demonstrating a -7.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Krebs Biochemicals and Industries Limited's stock price ₹48.33 by its total outstanding shares 21560586 (21.56 Million).
Krebs Biochemicals and Industries Limited Market Cap History: 2016 to 2026
Krebs Biochemicals and Industries Limited's market capitalization history from 2016 to 2026. Data shows change from $19.67 Million to $12.03 Million (-7.60% CAGR).
Krebs Biochemicals and Industries Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Krebs Biochemicals and Industries Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.04x
Krebs Biochemicals and Industries Limited's market cap is 0.04 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $19.67 Million | $12.90 Million | -$163.20 Million | 1.53x | N/A |
| 2017 | $34.37 Million | $16.95 Million | -$160.49 Million | 2.03x | N/A |
| 2018 | $28.37 Million | $254.09 Million | -$178.25 Million | 0.11x | N/A |
| 2019 | $19.38 Million | $371.33 Million | -$200.12 Million | 0.05x | N/A |
| 2020 | $34.62 Million | $235.84 Million | -$288.72 Million | 0.15x | N/A |
| 2021 | $48.26 Million | $386.06 Million | -$283.59 Million | 0.13x | N/A |
| 2022 | $27.30 Million | $597.03 Million | -$445.27 Million | 0.05x | N/A |
| 2023 | $19.51 Million | $521.34 Million | -$246.92 Million | 0.04x | N/A |
| 2024 | $23.15 Million | $504.21 Million | -$197.28 Million | 0.05x | N/A |
| 2025 | $17.19 Million | $433.12 Million | -$269.39 Million | 0.04x | N/A |
Competitor Companies of KREBSBIO by Market Capitalization
Companies near Krebs Biochemicals and Industries Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Krebs Biochemicals and Industries Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Krebs Biochemicals and Industries Limited Historical Marketcap From 2016 to 2026
Between 2016 and today, Krebs Biochemicals and Industries Limited's market cap moved from $19.67 Million to $ 12.03 Million, with a yearly change of -7.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹12.03 Million | -30.00% |
| 2025 | ₹17.19 Million | -25.76% |
| 2024 | ₹23.15 Million | +18.69% |
| 2023 | ₹19.51 Million | -28.55% |
| 2022 | ₹27.30 Million | -43.44% |
| 2021 | ₹48.26 Million | +39.41% |
| 2020 | ₹34.62 Million | +78.61% |
| 2019 | ₹19.38 Million | -31.68% |
| 2018 | ₹28.37 Million | -17.46% |
| 2017 | ₹34.37 Million | +74.75% |
| 2016 | ₹19.67 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Krebs Biochemicals and Industries Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.03 Million USD |
| MoneyControl | $12.03 Million USD |
| MarketWatch | $12.03 Million USD |
| marketcap.company | $12.03 Million USD |
| Reuters | $12.03 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.